Effect of topical steroids on nasal nitric oxide production in children with perennial allergic rhinitis: a pilot study.
It has been hypothesized that concentrations of exhaled nitric oxide (NO) may be related to the extent of cytokine-mediated airway inflammation. Recent findings indicate the nasal airways as an important site of NO production. Our objective was to evaluate whether children with allergic rhinitis show different nasal NO levels when compared with normal healthy subjects and the effect of topical steroids and anti-histamine therapy. We have measured the concentration of NO drawn from the nose of 21 children (5-17 years old) affected by perennial allergic rhinitis (house dust mite) out of therapy for at least 3 weeks. Thirteen children were then treated with nasal beclomethasone dipropionate (BDP) (400 micrograms daily) and eight subjects with nasal anti-histamine levocabastine (200 micrograms daily). Measurements were performed before and after 10 days of treatment. As a control group we evaluated 21 healthy children aged 5-15 years. To measure NO we used a chemiluminescence analyser. Before treatment the whole group of children with allergic rhinitis showed a mean (+/- SEM) nasal NO concentration of 267 +/- 18 ppb, significantly higher (P < 0.01) than the control group (186 +/- 15 ppb). The group of children treated with BDP showed, after 10 days of therapy, a significant (P < 0.05) decrease of nasal NO concentration (271 +/- 21 ppb vs. 212 +/- 20 ppb). Indeed, in the group treated with levocabastine, nasal NO concentrations did not present a significant difference (P not significant) compared with baseline (261 +/- 33 ppb and 252 +/- 31 ppb, respectively). These data suggest that (1) children with allergic rhinitis have higher levels of nasal NO than non-atopic controls and (2) intranasal steroid therapy significantly reduces nasal NO production in children with allergic rhinitis. We speculate that the allergic inflammatory response may influence the nasal NO levels and that NO measurements may be a useful marker of nasal inflammation.
Baraldi
E
E
Department of Paediatrics, University of Padova School of Medicine, Italy.
Azzolin
N M
NM
Carrà
S
S
Dario
C
C
Marchesini
L
L
Zacchello
F
F
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001507:Beclomethasone / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism*; D010865:Pilot Projects; D010880:Piperidines / Q000008:administration & dosage*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy* / Q000378:metabolism*; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D006634:Histamine H1 Antagonists; D010880:Piperidines; D009569:Nitric Oxide; C047340:levocabastine; D001507:Beclomethasone